Priority Review Vouchers Have Helped To Improve Access To Drugs Targeting Neglected Diseases

FILE – This April 28, 2010, file photo shows the GlaxoSmithKline offices in London. On July 20, 2018, the Food and Drug Administration approved GlaxoSmithKline’s Krintafel, a one-dose treatment to prevent relapses of malaria. AP PhotoKirsty Wigglesworth, File ASSOCIATED PRESS The Food and Drug Administration’s FDA Priority Review Vouchers PRVs for neglected tropical diseases NTDs…

The Week Ahead: Medicine manufacturers and middlemen

For the second time in two weeks, the price of insulin will be under scrutiny on Capitol Hill in the week ahead. On Tuesday, the trio of companies making insulin in the U.S. is due before a House subcommittee that has seized on the diabetes medicine as definitive evidence of prescription drug prices spiraling out…